Efficacy and safety of bromfenac for the treatment of corneal ulcer pain.

Abstract

PURPOSE:

To evaluate the efficacy and safety of bromfenac ophthalmic solution 0.09% (Xibrom™, ISTA Pharmaceuticals Inc., Irvine, CA, USA) for treating pain associated with corneal ulcers.

METHODS:

Twenty-five eyes of 24 patients with corneal infiltrates (bacterial or fungal) were treated with appropriate anti-infective agents along with bromfenac twice daily for up to 102 days to treat the pain caused by the infection. Follow-up visits were frequent in the first 2 weeks upon initiation of treatment, then at least weekly until infections were resolved. The best corrected visual acuity, location, size, and density of corneal infiltrates, the size and presence of a corneal epithelial defect, subjective eye pain (scale of 0-4) and time to pain resolution, the ability to conduct daily activities, and adverse events were recorded at each follow-up visit. The results of these treated patients were compared with those of 10 control eyes with corneal infiltrates (bacterial or fungal) where appropriate anti-infectives were used without adjunct medications.

RESULTS:

Fifty-two percent of bromfenac-treated patients reported no pain by day 3, compared with 0% of untreated controls (P=0.023). Most of the treated patients' epithelium healed by day 20 (68%) compared with only 10% of controls (P=0.040). Most bromfenac-treated patients (71%) returned to normal activities within 2 days of starting treatment with bromfenac, compared with 0% of controls (P=0.018). No adverse events were recorded.

CONCLUSION:

Bromfenac was effective in treating pain associated with infectious keratitis and did not delay corneal epithelialization nor cause any corneal adverse events in this group of 25 eyes.

• Authors: Barry A Schechter, William Trattler
• Journal: Advances in therapy (Adv Ther) Vol. 27 Issue 10 Pg. 756-61 (Oct 2010) ISSN: 1865-8652 [Electronic] United States
• PMID: 20845001 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Anti-Infective Agents, Local
• Anti-Inflammatory Agents, Non-Steroidal
• Benzophenones
• Bromobenzenes
• Ophthalmic Solutions
• bromfenac

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Anti-Infective Agents, Local (therapeutic use)
• Anti-Inflammatory Agents, Non-Steroidal (administration & dosage, adverse effects, therapeutic use)
• Benzophenones (administration & dosage, adverse effects, therapeutic use)
• Bromobenzenes (administration & dosage, adverse effects, therapeutic use)
• Corneal Ulcer (complications)
• Female
• Humans
• Male
• Middle Aged
• Ophthalmic Solutions
• Pain (drug therapy, etiology)
• Prospective Studies
• Young Adult